{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:28:52Z","timestamp":1790710132429,"version":"4.1.0"},"reference-count":161,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2024ZD0519800"],"award-info":[{"award-number":["2024ZD0519800"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","award":["2024B01J1154"],"award-info":[{"award-number":["2024B01J1154"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012541","name":"Guangdong Innovative and Entrepreneurial Research Team Program","doi-asserted-by":"publisher","award":["2019BT02Y198"],"award-info":[{"award-number":["2019BT02Y198"]}],"id":[{"id":"10.13039\/100012541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012541","name":"Guangdong Innovative and Entrepreneurial Research Team Program","doi-asserted-by":"publisher","award":["2023-2025"],"award-info":[{"award-number":["2023-2025"]}],"id":[{"id":"10.13039\/100012541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012541","name":"Guangdong Innovative and Entrepreneurial Research Team Program","doi-asserted-by":"publisher","award":["2023P-ZD14"],"award-info":[{"award-number":["2023P-ZD14"]}],"id":[{"id":"10.13039\/100012541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M763777"],"award-info":[{"award-number":["2024M763777"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M753784"],"award-info":[{"award-number":["2024M753784"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022B1515020101"],"award-info":[{"award-number":["2022B1515020101"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007162","name":"Department of Science and Technology of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017369","name":"Scientific and Technological Planning Project of Guangzhou City","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017369","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"publisher","award":["2023B1212060013"],"award-info":[{"award-number":["2023B1212060013"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82222029"],"award-info":[{"award-number":["82222029"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82330056"],"award-info":[{"award-number":["82330056"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82488101"],"award-info":[{"award-number":["82488101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403456"],"award-info":[{"award-number":["82403456"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92159303"],"award-info":[{"award-number":["92159303"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020084","name":"Guangzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["20212200003"],"award-info":[{"award-number":["20212200003"]}],"id":[{"id":"10.13039\/501100020084","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2021YFA1300602"],"award-info":[{"award-number":["2021YFA1300602"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.trecan.2025.09.003","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T06:04:48Z","timestamp":1760076288000},"page":"48-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["RNA vaccines for cancer: revolutionizing immunization strategies"],"prefix":"10.1016","volume":"12","author":[{"given":"Di","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2025.09.003_bb0005","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1384","article-title":"mRNA vaccine in cancer therapy: current advance and future outlook","volume":"13","author":"Li","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.trecan.2025.09.003_bb0010","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","article-title":"Cancer vaccines as promising immuno-therapeutics: platforms and current progress","volume":"15","author":"Liu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0015","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.trecan.2025.09.003_bb0020","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1126\/science.1546298","article-title":"Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA","volume":"255","author":"Jirikowski","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.trecan.2025.09.003_bb0025","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/eji.1830230749","article-title":"Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA","volume":"23","author":"Martinon","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0030","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.3390\/ijms24032700","article-title":"A comprehensive review of mRNA vaccines","volume":"24","author":"Gote","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.trecan.2025.09.003_bb0035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.trecan.2025.09.003_bb0040","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2013 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.trecan.2025.09.003_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1029069","article-title":"mRNA vaccines for cancer immunotherapy","volume":"13","author":"Vishweshwaraiah","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0050","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41467-022-28776-w","article-title":"Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics","volume":"13","author":"Leppek","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2025.09.003_bb0055","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00262-025-03992-7","article-title":"Neoantigen-based mRNA vaccine exhibits superior anti-tumor activity compared to synthetic long peptides in an in vivo lung carcinoma model","volume":"74","author":"Nguyen","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.trecan.2025.09.003_bb0060","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41591-021-01449-9","article-title":"Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19\/BNT162b2 vaccination","volume":"27","author":"Barros-Martins","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2025.09.003_bb0065","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41591-021-01464-w","article-title":"Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19\/mRNA vaccination","volume":"27","author":"Schmidt","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2025.09.003_bb0070","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.09.003_bb0075","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.09.003_bb0080","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn7842","article-title":"Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses","volume":"14","author":"Sievers","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2025.09.003_bb0085","doi-asserted-by":"crossref","first-page":"e670","DOI":"10.1016\/S2666-5247(23)00216-1","article-title":"Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial","volume":"4","author":"Leung","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.trecan.2025.09.003_bb0090","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41590-023-01692-x","article-title":"Repeated mRNA vaccination sequentially boosts SARS-CoV-2-specific CD8+ T cells in persons with previous COVID-19","volume":"25","author":"Ford","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0095","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2025.09.003_bb0100","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41434-020-00204-y","article-title":"Self-amplifying RNA vaccines for infectious diseases","volume":"28","author":"Bloom","year":"2020","journal-title":"Gene Ther."},{"key":"10.1016\/j.trecan.2025.09.003_bb0105","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3390\/pathogens12010138","article-title":"Self-amplifying RNA vaccine candidates: alternative platforms for mRNA vaccine development","volume":"12","author":"Schmidt","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.trecan.2025.09.003_bb0110","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.tibtech.2023.05.007","article-title":"Rise of the RNA machines \u2013 self-amplification in mRNA vaccine design","volume":"41","author":"Comes","year":"2023","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0115","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/vaccines9020097","article-title":"An update on self-amplifying mRNA vaccine development","volume":"9","author":"Blakney","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.trecan.2025.09.003_bb0120","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1473-3099(23)00650-3","article-title":"Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial","volume":"24","author":"Oda","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.trecan.2025.09.003_bb0125","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jconrel.2022.05.043","article-title":"Circular RNA: an emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines","volume":"348","author":"Liu","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.trecan.2025.09.003_bb0130","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41587-022-01393-0","article-title":"Engineering circular RNA for enhanced protein production","volume":"41","author":"Chen","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0135","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1038\/s41467-018-05096-6","article-title":"Engineering circular RNA for potent and stable translation in eukaryotic cells","volume":"9","author":"Wesselhoeft","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2025.09.003_bb0140","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.molcel.2019.02.015","article-title":"RNA circularization diminishes immunogenicity and can extend translation duration in vivo","volume":"74","author":"Wesselhoeft","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.trecan.2025.09.003_bb0145","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1093\/nar\/gkv045","article-title":"RNA circularization strategies in vivo and in vitro","volume":"43","author":"Petkovic","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.trecan.2025.09.003_bb0150","doi-asserted-by":"crossref","first-page":"13247","DOI":"10.3390\/ijms232113247","article-title":"Pros and cons of in vitro methods for circular RNA preparation","volume":"23","author":"Lee","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.trecan.2025.09.003_bb0155","doi-asserted-by":"crossref","first-page":"975","DOI":"10.7150\/ijms.71840","article-title":"Advances in circular RNA and its applications","volume":"19","author":"Zhao","year":"2022","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.trecan.2025.09.003_bb0160","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.7150\/thno.98214","article-title":"Developing an enhanced chimeric permuted intron-exon system for circular RNA therapeutics","volume":"14","author":"Wang","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.trecan.2025.09.003_bb0165","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1093\/nar\/20.20.5357","article-title":"Group I permuted intron-exon (PIE) sequences self-splice to produce circular exons","volume":"20","author":"Puttaraju","year":"1992","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.trecan.2025.09.003_bb0170","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.omtn.2023.07.034","article-title":"Efficient circular RNA engineering by end-to-end self-targeting and splicing reaction using Tetrahymena group I intron ribozyme","volume":"33","author":"Lee","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.trecan.2025.09.003_bb0175","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.cell.2022.03.044","article-title":"Circular RNA vaccines against SARS-CoV-2 and emerging variants","volume":"185","author":"Qu","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2025.09.003_bb0180","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41541-024-00963-4","article-title":"CircRNA based multivalent neuraminidase vaccine induces broad protection against influenza viruses in mice","volume":"9","author":"Yue","year":"2024","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.trecan.2025.09.003_bb0185","doi-asserted-by":"crossref","first-page":"6422","DOI":"10.7150\/thno.77350","article-title":"Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies","volume":"12","author":"Li","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.trecan.2025.09.003_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105370","article-title":"A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera","volume":"204","author":"Seephetdee","year":"2022","journal-title":"Antivir. Res."},{"key":"10.1016\/j.trecan.2025.09.003_bb0195","article-title":"Lnc-H19-derived protein shapes the immunosuppressive microenvironment of glioblastoma","volume":"5","author":"Chen","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.trecan.2025.09.003_bb0200","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2406434121","article-title":"CXCL13 promotes broad immune responses induced by circular RNA vaccines","volume":"121","author":"Wan","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2025.09.003_bb0205","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2302191120","article-title":"Circular RNA vaccine induces potent T cell responses","volume":"120","author":"Amaya","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2025.09.003_bb0210","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41392-023-01561-x","article-title":"Circular RNA vaccine in disease prevention and treatment","volume":"8","author":"Niu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.trecan.2025.09.003_bb0215","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-015-0068-y","article-title":"Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I\/IIa study","volume":"3","author":"K\u00fcbler","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2025.09.003_bb0220","doi-asserted-by":"crossref","first-page":"v408","DOI":"10.1093\/annonc\/mdx376.014","article-title":"Results of the randomized, placebo-controlled phase I\/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"28","author":"Stenzl","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0225","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40425-019-0520-5","article-title":"Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer","volume":"7","author":"Papachristofilou","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2025.09.003_bb0230","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.09.003_bb0235","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41422-024-00990-9","article-title":"Combination therapy of KRAS G12V mRNA vaccine and pembrolizumab: clinical benefit in patients with advanced solid tumors","volume":"34","author":"Wang","year":"2024","journal-title":"Cell Res."},{"key":"10.1016\/j.trecan.2025.09.003_bb0240","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1038\/s41467-020-19288-6","article-title":"Immune modulatory effects of oncogenic KRAS in cancer","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2025.09.003_bb0245","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41591-024-02851-9","article-title":"A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results","volume":"30","author":"Rappaport","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2025.09.003_bb0250","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","article-title":"Challenges in developing personalized neoantigen cancer vaccines","volume":"24","author":"Katsikis","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0255","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41591-022-01937-6","article-title":"Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results","volume":"28","author":"Palmer","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2025.09.003_bb0260","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.09.003_bb0265","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2025.09.003_bb0270","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA9512","article-title":"Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial [abstract]","volume":"42","author":"Weber","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0275","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.ccell.2024.05.005","article-title":"RNA vaccines for cancer: principles to practice","volume":"42","author":"Guasp","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2025.09.003_bb0280","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrclinonc.2014.111","article-title":"Therapeutic vaccines for cancer: an overview of clinical trials","volume":"11","author":"Melero","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0285","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.trecan.2025.09.003_bb0290","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0295","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ccell.2022.05.015","article-title":"Cancer vaccines","volume":"40","author":"Schiller","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2025.09.003_bb0300","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn3464","article-title":"Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice","volume":"15","author":"Ramos da Silva","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2025.09.003_bb0305","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1016\/j.ymthe.2024.04.036","article-title":"Development of an mRNA-based therapeutic vaccine mHTV-03E2 for high-risk HPV-related malignancies","volume":"32","author":"Wang","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.trecan.2025.09.003_bb0310","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1007\/s12274-022-5254-x","article-title":"A lipid-based LMP2-mRNA vaccine to treat nasopharyngeal carcinoma","volume":"16","author":"Guo","year":"2023","journal-title":"Nano Res"},{"key":"10.1016\/j.trecan.2025.09.003_bb0315","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s12951-023-02069-w","article-title":"LMP2-mRNA lipid nanoparticle sensitizes EBV-related tumors to anti-PD-1 therapy by reversing T cell exhaustion","volume":"21","author":"Xiang","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0320","article-title":"mRNA-based vaccines targeting the T-cell epitope-rich domain of Epstein Barr virus latent proteins elicit robust anti-tumor immunity in mice","volume":"10","author":"Zhao","year":"2023","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.trecan.2025.09.003_bb0325","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41590-023-01664-1","article-title":"Non-mutational neoantigens in disease","volume":"25","author":"Stern","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0330","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41587-021-01038-8","article-title":"Identification of tumor antigens with immunopeptidomics","volume":"40","author":"Chong","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0335","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abm6360","article-title":"Epigenetically controlled tumor antigens derived from splice junctions between exons and transposable elements","volume":"8","author":"Burbage","year":"2023","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0340","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abm6359","article-title":"Noncanonical splicing junctions between exons and transposable elements represent a source of immunogenic recurrent neo-antigens in patients with lung cancer","volume":"8","author":"Merlotti","year":"2023","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0345","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1016\/j.cell.2021.05.038","article-title":"Pharmacologic modulation of RNA splicing enhances anti-tumor immunity","volume":"184","author":"Lu","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2025.09.003_bb0350","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41587-022-01464-2","article-title":"Post-translational modifications reshape the antigenic landscape of the MHC I immunopeptidome in tumors","volume":"41","author":"Kacen","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0355","doi-asserted-by":"crossref","DOI":"10.1126\/science.adk3487","article-title":"Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition","volume":"388","author":"Ely","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.trecan.2025.09.003_bb0360","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-024-08552-0","article-title":"Tumour-wide RNA splicing aberrations generate actionable public neoantigens","volume":"639","author":"Kwok","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.09.003_bb0365","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41586-023-06834-7","article-title":"Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides","volume":"625","author":"Huang","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.09.003_bb0370","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.it.2025.06.002","article-title":"Cryptic but critical: non-canonical antigens in cancer immunotherapy","volume":"46","author":"Goncalves","year":"2025","journal-title":"Trends Immunol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0375","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coi.2016.04.005","article-title":"Mass spectrometry-based antigen discovery for cancer immunotherapy","volume":"41","author":"Bassani-Sternberg","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0380","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1038\/s41467-023-39570-7","article-title":"Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identification","volume":"14","author":"Tretter","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2025.09.003_bb0385","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","article-title":"Identification of neoantigens for individualized therapeutic cancer vaccines","volume":"21","author":"Lang","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.trecan.2025.09.003_bb0390","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.semcancer.2023.02.007","article-title":"Artificial intelligence in cancer immunotherapy: applications in neoantigen recognition, antibody design and immunotherapy response prediction","volume":"91","author":"Li","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0395","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/s42256-024-00901-y","article-title":"Sliding-attention transformer neural architecture for predicting T cell receptor\u2013antigen\u2013human leucocyte antigen binding","volume":"6","author":"Feng","year":"2024","journal-title":"Nat. Mach. Intell."},{"key":"10.1016\/j.trecan.2025.09.003_bb0400","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.immuni.2023.09.002","article-title":"Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction","volume":"56","author":"M\u00fcller","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2025.09.003_bb0405","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41587-024-02420-y","article-title":"A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy","volume":"43","author":"Huber","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0410","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1586\/erv.10.169","article-title":"ELISpot for measuring human immune responses to vaccines","volume":"10","author":"Slota","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.trecan.2025.09.003_bb0415","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/nprot.2012.037","article-title":"Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers","volume":"7","author":"Andersen","year":"2012","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.trecan.2025.09.003_bb0420","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12943-023-01844-5","article-title":"The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells","volume":"22","author":"Li","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.trecan.2025.09.003_bb0425","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1126\/science.1093620","article-title":"Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8","volume":"303","author":"Heil","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.trecan.2025.09.003_bb0430","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature04734","article-title":"Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses","volume":"441","author":"Kato","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.09.003_bb0435","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2025.09.003_bb0440","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/s41580-023-00622-x","article-title":"Regulation and functions of non-m6A mRNA modifications","volume":"24","author":"Sun","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0445","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2025.09.003_bb0450","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.trecan.2025.09.003_bb0455","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.789427","article-title":"The critical contribution of pseudouridine to mRNA COVID-19 vaccines","volume":"9","author":"Morais","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0460","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.apsb.2023.11.003","article-title":"A novel deep generative model for mRNA vaccine development: Designing 5\u2032 UTRs with N1-methyl-pseudouridine modification","volume":"14","author":"Tang","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.trecan.2025.09.003_bb0465","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.molcel.2019.07.016","article-title":"N6-methyladenosine modification controls circular RNA immunity","volume":"76","author":"Chen","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.trecan.2025.09.003_bb0470","doi-asserted-by":"crossref","first-page":"7511","DOI":"10.1093\/nar\/gkw551","article-title":"mRNA capping: biological functions and applications","volume":"44","author":"Ramanathan","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.trecan.2025.09.003_bb0475","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrmicro2675","article-title":"Conventional and unconventional mechanisms for capping viral mRNA","volume":"10","author":"Decroly","year":"2011","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0480","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.molcel.2015.04.004","article-title":"Molecular basis of transcription-coupled pre-mRNA capping","volume":"58","author":"Martinez-Rucobo","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.trecan.2025.09.003_bb0485","article-title":"Cap 1 messenger RNA synthesis with co-transcriptional CleanCap analog by in vitro transcription","volume":"1","author":"Henderson","year":"2021","journal-title":"Curr. Protoc."},{"key":"10.1016\/j.trecan.2025.09.003_bb0490","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkad019","article-title":"Versatile strategy using vaccinia virus-capping enzyme to synthesize functional 5\u2032 cap-modified mRNAs","volume":"51","author":"Ohno","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.trecan.2025.09.003_bb0495","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.tibs.2024.06.013","article-title":"Beyond simple tails: poly(A) tail-mediated RNA epigenetic regulation","volume":"49","author":"Liu","year":"2024","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.trecan.2025.09.003_bb0500","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1146\/annurev-biochem-060713-035802","article-title":"The scanning mechanism of eukaryotic translation initiation","volume":"83","author":"Hinnebusch","year":"2014","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.trecan.2025.09.003_bb0505","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41580-021-00417-y","article-title":"Roles of mRNA poly(A) tails in regulation of eukaryotic gene expression","volume":"23","author":"Passmore","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0510","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41587-024-02174-7","article-title":"Branched chemically modified poly(A) tails enhance the translation capacity of mRNA","volume":"43","author":"Chen","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0515","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1038\/s41467-024-49508-2","article-title":"Optimizing 5\u2032UTRs for mRNA-delivered gene editing using deep learning","volume":"15","author":"Castillo-Hair","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2025.09.003_bb0520","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3390\/ijms25020888","article-title":"Untranslated region sequences and the efficacy of mRNA vaccines against tuberculosis","volume":"25","author":"Reshetnikov","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.trecan.2025.09.003_bb0525","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41541-023-00684-0","article-title":"Analyzing immune responses to varied mRNA and protein vaccine sequences","volume":"8","author":"Park","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.trecan.2025.09.003_bb0530","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrm.2017.91","article-title":"Codon optimality, bias and usage in translation and mRNA decay","volume":"19","author":"Hanson","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0535","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.cell.2015.02.029","article-title":"Codon optimality is a major determinant of mRNA stability","volume":"160","author":"Presnyak","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2025.09.003_bb0540","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29183","article-title":"Viral codon optimization on SARS-CoV-2 Spike boosts immunity in the development of COVID-19 mRNA vaccines","volume":"95","author":"Lai","year":"2023","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0545","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","article-title":"Algorithm for optimized mRNA design improves stability and immunogenicity","volume":"621","author":"Zhang","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.09.003_bb0550","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.canlet.2020.04.006","article-title":"Translatable circRNAs and lncRNAs: driving mechanisms and functions of their translation products","volume":"483","author":"Kong","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.trecan.2025.09.003_bb0555","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.biochi.2019.06.015","article-title":"How are circRNAs translated by non-canonical initiation mechanisms?","volume":"164","author":"Diallo","year":"2019","journal-title":"Biochimie"},{"key":"10.1016\/j.trecan.2025.09.003_bb0560","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1016\/j.molcel.2021.07.042","article-title":"Structured elements drive extensive circular RNA translation","volume":"81","author":"Chen","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.trecan.2025.09.003_bb0565","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.trecan.2025.09.003_bb0570","article-title":"Lipid nanoparticles optimized for targeting and release of nucleic acid","volume":"36","author":"Jia","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.trecan.2025.09.003_bb0575","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","article-title":"Chemistry of lipid nanoparticles for RNA delivery","volume":"55","author":"Eygeris","year":"2022","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.trecan.2025.09.003_bb0580","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202001294","article-title":"Environment-responsive lipid\/siRNA nanoparticles for cancer therapy","volume":"10","author":"Lu","year":"2021","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.trecan.2025.09.003_bb0585","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2025.09.003_bb0590","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s42003-023-04555-1","article-title":"Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals","volume":"6","author":"Connors","year":"2023","journal-title":"Commun. Biol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0595","article-title":"mRNA vaccines against SARS-CoV-2 variants delivered by lipid nanoparticles based on novel ionizable lipids","volume":"32","author":"Chen","year":"2022","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.trecan.2025.09.003_bb0600","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.1038\/s41467-024-50093-7","article-title":"Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation","volume":"15","author":"Su","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2025.09.003_bb0605","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0610","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2109256118","article-title":"On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles","volume":"118","author":"Dilliard","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2025.09.003_bb0615","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41565-024-01747-6","article-title":"Combinatorial design of siloxane-incorporated lipid nanoparticles augments intracellular processing for tissue-specific mRNA therapeutic delivery","volume":"20","author":"Xue","year":"2025","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0620","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/j.cell.2024.04.003","article-title":"RNA aggregates harness the danger response for potent cancer immunotherapy","volume":"187","author":"Mendez-Gomez","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2025.09.003_bb0625","article-title":"Polymer-based mRNA delivery strategies for advanced therapies","volume":"12","author":"Yang","year":"2023","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.trecan.2025.09.003_bb0630","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00063030-200822050-00004","article-title":"The impact of PEGylation on biological therapies","volume":"22","author":"Veronese","year":"2008","journal-title":"Biodrugs"},{"key":"10.1016\/j.trecan.2025.09.003_bb0635","doi-asserted-by":"crossref","first-page":"35835","DOI":"10.1021\/acsami.0c08268","article-title":"Surface-functionalized PEGylated nanoparticles deliver messenger RNA to pulmonary immune cells","volume":"12","author":"Ke","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.trecan.2025.09.003_bb0640","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq0603","article-title":"Polymer nanoparticles deliver mRNA to the lung for mucosal vaccination","volume":"15","author":"Suberi","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2025.09.003_bb0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104586","article-title":"Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trial","volume":"91","author":"Gui","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.trecan.2025.09.003_bb0650","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1039\/C8BM00908B","article-title":"Cationic lipid-assisted nanoparticles for delivery of mRNA cancer vaccine","volume":"6","author":"Fan","year":"2018","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.trecan.2025.09.003_bb0655","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1021\/acsnano.7b07874","article-title":"Macrophage-specific in vivo gene editing using cationic lipid-assisted polymeric nanoparticles","volume":"12","author":"Luo","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.trecan.2025.09.003_bb0660","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev-chembioeng-101121-070232","article-title":"Peptide-based vectors: a biomolecular engineering strategy for gene delivery","volume":"14","author":"Urandur","year":"2023","journal-title":"Annu. Rev. Chem. Biomol. Eng."},{"key":"10.1016\/j.trecan.2025.09.003_bb0665","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1126\/science.abg6155","article-title":"Mammalian retrovirus-like protein PEG10 packages its own mRNA and can be pseudotyped for mRNA delivery","volume":"373","author":"Segel","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.trecan.2025.09.003_bb0670","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/cr.2016.157","article-title":"Dendritic cell-based immunotherapy","volume":"27","author":"Sabado","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.trecan.2025.09.003_bb0675","doi-asserted-by":"crossref","first-page":"237","DOI":"10.7150\/thno.21945","article-title":"Exosome theranostics: biology and translational medicine","volume":"8","author":"He","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.trecan.2025.09.003_bb0680","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1021\/acs.nanolett.1c00094","article-title":"Natural or synthetic RNA delivery: a stoichiometric comparison of extracellular vesicles and synthetic nanoparticles","volume":"21","author":"Murphy","year":"2021","journal-title":"Nano Lett."},{"key":"10.1016\/j.trecan.2025.09.003_bb0685","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41580-020-0251-y","article-title":"RNA delivery by extracellular vesicles in mammalian cells and its applications","volume":"21","author":"O\u2019Brien","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0690","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41565-023-01580-3","article-title":"Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity","volume":"19","author":"Liu","year":"2024","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0695","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1126\/science.aay5967","article-title":"An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors","volume":"367","author":"Reinhard","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.trecan.2025.09.003_bb0700","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1016\/j.cell.2022.10.006","article-title":"Systemic vaccination induces CD8+ T cells and remodels the tumor microenvironment","volume":"185","author":"Baharom","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2025.09.003_bb2005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.612747","article-title":"Optimize prime\/boost vaccine strategies: trained immunity as a new player in the game","volume":"12","author":"Palgen","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2025.09.003_bb2010","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004022","article-title":"CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1\/PD-L1 immunotherapy","volume":"10","author":"Xiao","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2025.09.003_bb2015","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","article-title":"Heterologous prime-boost vaccination","volume":"21","author":"Lu","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0705","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.it.2022.04.010","article-title":"Turning cold tumors hot: from molecular mechanisms to clinical applications","volume":"43","author":"Zhang","year":"2022","journal-title":"Trends Immunol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0710","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12943-023-01885-w","article-title":"Exploiting innate immunity for cancer immunotherapy","volume":"22","author":"Yi","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.trecan.2025.09.003_bb0715","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-020-00916-z","article-title":"cGAS-STING, an important pathway in cancer immunotherapy","volume":"13","author":"Jiang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0720","doi-asserted-by":"crossref","DOI":"10.1093\/nsr\/nwad214","article-title":"STING agonist-boosted mRNA immunization via intelligent design of nanovaccines for enhancing cancer immunotherapy","volume":"10","author":"Zhou","year":"2023","journal-title":"Natl. Sci. Rev."},{"key":"10.1016\/j.trecan.2025.09.003_bb0725","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.ymthe.2021.03.002","article-title":"mRNA-encoded, constitutively active STING(V155M) is a potent genetic adjuvant of antigen-specific CD8+ T cell response","volume":"29","author":"Tse","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.trecan.2025.09.003_bb0730","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1158\/0008-5472.CAN-11-2957","article-title":"Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy","volume":"72","author":"Van Lint","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2025.09.003_bb0735","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2326-6066.CIR-15-0163","article-title":"Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells","volume":"4","author":"Van Lint","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.trecan.2025.09.003_bb0740","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000329","article-title":"TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma","volume":"8","author":"De Keersmaecker","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2025.09.003_bb0745","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1200\/JCO.2015.63.4121","article-title":"Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma","volume":"34","author":"Wilgenhof","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0750","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-024-03334-7","article-title":"Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial","volume":"31","author":"Lopez","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2025.09.003_bb0755","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41571-024-00867-1","article-title":"Personalized neoantigen mRNA vaccine mitigates melanoma recurrence","volume":"21","author":"Killock","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.09.003_bb0760","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","article-title":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial","volume":"29","author":"Mackensen","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2025.09.003_bb0765","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.trecan.2025.09.003_bb0770","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.trecan.2025.09.003_bb0775","doi-asserted-by":"crossref","first-page":"19550","DOI":"10.1021\/acsnano.3c05635","article-title":"mRNA cancer vaccines: construction and boosting strategies","volume":"17","author":"Liu","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.trecan.2025.09.003_bb0780","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41392-024-01824-1","article-title":"Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects","volume":"9","author":"Fu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.trecan.2025.09.003_bb0785","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/cac2.12316","article-title":"The theory of tumor ecosystem","volume":"42","author":"Chen","year":"2022","journal-title":"Cancer Commun. (Lond.)"},{"key":"10.1016\/j.trecan.2025.09.003_bb0790","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1200\/JCO.2019.37.15_suppl.2641","article-title":"A phase I study (E011-MEL) of a TriMix-based mRNA immunotherapy (ECI-006) in resected melanoma patients: analysis of safety and immunogenicity [abstract]","volume":"37","author":"Fernandez","year":"2019","journal-title":"J. Clin. Oncol."}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803325002316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803325002316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:54:55Z","timestamp":1778882095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803325002316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":161,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2405803325002316"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2025.09.003","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RNA vaccines for cancer: revolutionizing immunization strategies","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2025.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}